nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—KIT—thymus cancer	0.719	1	CbGaD
Imatinib—CA3—pericardium—thymus cancer	0.00843	0.0898	CbGeAlD
Imatinib—Osteonecrosis—Octreotide—thymus cancer	0.00459	0.0319	CcSEcCtD
Imatinib—Hepatitis cholestatic—Octreotide—thymus cancer	0.00424	0.0295	CcSEcCtD
Imatinib—Ponatinib—KIT—thymus cancer	0.00359	0.575	CrCbGaD
Imatinib—Renal pain—Octreotide—thymus cancer	0.00325	0.0226	CcSEcCtD
Imatinib—Creatine phosphokinase increased—Octreotide—thymus cancer	0.00325	0.0226	CcSEcCtD
Imatinib—Loose stools—Octreotide—thymus cancer	0.00309	0.0215	CcSEcCtD
Imatinib—Haematoma—Octreotide—thymus cancer	0.00272	0.0189	CcSEcCtD
Imatinib—Nilotinib—KIT—thymus cancer	0.00265	0.425	CrCbGaD
Imatinib—Nail disorder—Octreotide—thymus cancer	0.00264	0.0183	CcSEcCtD
Imatinib—Intestinal obstruction—Octreotide—thymus cancer	0.00251	0.0174	CcSEcCtD
Imatinib—Blood creatine phosphokinase increased—Octreotide—thymus cancer	0.00248	0.0173	CcSEcCtD
Imatinib—Throat sore—Octreotide—thymus cancer	0.00237	0.0165	CcSEcCtD
Imatinib—Oropharyngeal discomfort—Octreotide—thymus cancer	0.00235	0.0163	CcSEcCtD
Imatinib—Herpes zoster—Octreotide—thymus cancer	0.00227	0.0158	CcSEcCtD
Imatinib—Petechiae—Octreotide—thymus cancer	0.00208	0.0144	CcSEcCtD
Imatinib—Neoplasm malignant—Octreotide—thymus cancer	0.002	0.0139	CcSEcCtD
Imatinib—ABCA3—pituitary gland—thymus cancer	0.002	0.0213	CbGeAlD
Imatinib—Contusion—Octreotide—thymus cancer	0.00196	0.0136	CcSEcCtD
Imatinib—DDR1—cardiac atrium—thymus cancer	0.00189	0.0201	CbGeAlD
Imatinib—Hyperbilirubinaemia—Octreotide—thymus cancer	0.00188	0.0131	CcSEcCtD
Imatinib—Oropharyngeal pain—Octreotide—thymus cancer	0.00188	0.0131	CcSEcCtD
Imatinib—Cellulitis—Octreotide—thymus cancer	0.00188	0.0131	CcSEcCtD
Imatinib—Herpes simplex—Octreotide—thymus cancer	0.00185	0.0129	CcSEcCtD
Imatinib—DDR1—pituitary gland—thymus cancer	0.00185	0.0197	CbGeAlD
Imatinib—Drug interaction—Octreotide—thymus cancer	0.00184	0.0128	CcSEcCtD
Imatinib—Hearing impaired—Octreotide—thymus cancer	0.0018	0.0125	CcSEcCtD
Imatinib—ABCA3—thyroid gland—thymus cancer	0.00172	0.0184	CbGeAlD
Imatinib—Phosphatase alkaline increased—Octreotide—thymus cancer	0.00171	0.0119	CcSEcCtD
Imatinib—Eructation—Octreotide—thymus cancer	0.00168	0.0117	CcSEcCtD
Imatinib—Hyperkalaemia—Octreotide—thymus cancer	0.00168	0.0117	CcSEcCtD
Imatinib—Influenza like illness—Octreotide—thymus cancer	0.00166	0.0115	CcSEcCtD
Imatinib—DDR1—thyroid gland—thymus cancer	0.00159	0.017	CbGeAlD
Imatinib—ABCA3—lung—thymus cancer	0.00157	0.0167	CbGeAlD
Imatinib—Mouth ulceration—Octreotide—thymus cancer	0.00155	0.0107	CcSEcCtD
Imatinib—Gynaecomastia—Octreotide—thymus cancer	0.00153	0.0106	CcSEcCtD
Imatinib—DDR1—lung—thymus cancer	0.00145	0.0154	CbGeAlD
Imatinib—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00143	0.00992	CcSEcCtD
Imatinib—Gastroenteritis—Octreotide—thymus cancer	0.0014	0.00973	CcSEcCtD
Imatinib—Deafness—Octreotide—thymus cancer	0.00139	0.00964	CcSEcCtD
Imatinib—Cardiac failure congestive—Octreotide—thymus cancer	0.00137	0.00951	CcSEcCtD
Imatinib—Arthritis—Octreotide—thymus cancer	0.00128	0.00888	CcSEcCtD
Imatinib—Hypoglycaemia—Octreotide—thymus cancer	0.00127	0.00884	CcSEcCtD
Imatinib—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00124	0.00863	CcSEcCtD
Imatinib—Pain in extremity—Octreotide—thymus cancer	0.00124	0.00863	CcSEcCtD
Imatinib—KIT—neck—thymus cancer	0.00121	0.0129	CbGeAlD
Imatinib—ABL2—pituitary gland—thymus cancer	0.0012	0.0128	CbGeAlD
Imatinib—PDGFRB—neck—thymus cancer	0.00118	0.0126	CbGeAlD
Imatinib—PIP4K2C—cardiac atrium—thymus cancer	0.00117	0.0124	CbGeAlD
Imatinib—Dehydration—Octreotide—thymus cancer	0.00115	0.00802	CcSEcCtD
Imatinib—PIP4K2C—pituitary gland—thymus cancer	0.00114	0.0121	CbGeAlD
Imatinib—Dry skin—Octreotide—thymus cancer	0.00114	0.00791	CcSEcCtD
Imatinib—Abdominal pain upper—Octreotide—thymus cancer	0.00113	0.00788	CcSEcCtD
Imatinib—PDGFRA—hematopoietic system—thymus cancer	0.00113	0.012	CbGeAlD
Imatinib—Cramp muscle—Octreotide—thymus cancer	0.00112	0.00777	CcSEcCtD
Imatinib—CA3—cardiac atrium—thymus cancer	0.00111	0.0119	CbGeAlD
Imatinib—Nasopharyngitis—Octreotide—thymus cancer	0.00111	0.00771	CcSEcCtD
Imatinib—Gastritis—Octreotide—thymus cancer	0.0011	0.00763	CcSEcCtD
Imatinib—Muscular weakness—Octreotide—thymus cancer	0.00109	0.00761	CcSEcCtD
Imatinib—CA3—pituitary gland—thymus cancer	0.00109	0.0116	CbGeAlD
Imatinib—Abdominal distension—Octreotide—thymus cancer	0.00108	0.00751	CcSEcCtD
Imatinib—Influenza—Octreotide—thymus cancer	0.00107	0.00746	CcSEcCtD
Imatinib—ABCA3—lymph node—thymus cancer	0.00107	0.0114	CbGeAlD
Imatinib—Pancreatitis—Octreotide—thymus cancer	0.00105	0.00731	CcSEcCtD
Imatinib—Sweating increased—Octreotide—thymus cancer	0.00104	0.00726	CcSEcCtD
Imatinib—ABL2—thyroid gland—thymus cancer	0.00104	0.0111	CbGeAlD
Imatinib—CA14—cardiac atrium—thymus cancer	0.00101	0.0108	CbGeAlD
Imatinib—Upper respiratory tract infection—Octreotide—thymus cancer	0.000997	0.00693	CcSEcCtD
Imatinib—CSF1R—hematopoietic system—thymus cancer	0.000991	0.0106	CbGeAlD
Imatinib—Pollakiuria—Octreotide—thymus cancer	0.000991	0.00689	CcSEcCtD
Imatinib—DDR1—lymph node—thymus cancer	0.000989	0.0105	CbGeAlD
Imatinib—PIP4K2C—bone marrow—thymus cancer	0.000985	0.0105	CbGeAlD
Imatinib—PIP4K2C—thyroid gland—thymus cancer	0.000983	0.0105	CbGeAlD
Imatinib—Weight increased—Octreotide—thymus cancer	0.000976	0.00679	CcSEcCtD
Imatinib—Weight decreased—Octreotide—thymus cancer	0.00097	0.00675	CcSEcCtD
Imatinib—Hyperglycaemia—Octreotide—thymus cancer	0.000967	0.00673	CcSEcCtD
Imatinib—Pneumonia—Octreotide—thymus cancer	0.000962	0.00669	CcSEcCtD
Imatinib—Depression—Octreotide—thymus cancer	0.000953	0.00663	CcSEcCtD
Imatinib—ABL2—lung—thymus cancer	0.000943	0.01	CbGeAlD
Imatinib—CA3—bone marrow—thymus cancer	0.000941	0.01	CbGeAlD
Imatinib—CA3—thyroid gland—thymus cancer	0.000938	0.01	CbGeAlD
Imatinib—Neuropathy peripheral—Octreotide—thymus cancer	0.000937	0.00652	CcSEcCtD
Imatinib—Jaundice—Octreotide—thymus cancer	0.000932	0.00648	CcSEcCtD
Imatinib—Conjunctivitis—Octreotide—thymus cancer	0.000929	0.00646	CcSEcCtD
Imatinib—Urinary tract infection—Octreotide—thymus cancer	0.000929	0.00646	CcSEcCtD
Imatinib—Haematuria—Octreotide—thymus cancer	0.000912	0.00634	CcSEcCtD
Imatinib—SLC47A1—hematopoietic system—thymus cancer	0.000905	0.00964	CbGeAlD
Imatinib—Hepatobiliary disease—Octreotide—thymus cancer	0.000904	0.00629	CcSEcCtD
Imatinib—Epistaxis—Octreotide—thymus cancer	0.000902	0.00627	CcSEcCtD
Imatinib—KIT—hematopoietic system—thymus cancer	0.0009	0.00959	CbGeAlD
Imatinib—Sinusitis—Octreotide—thymus cancer	0.000897	0.00624	CcSEcCtD
Imatinib—PIP4K2C—lung—thymus cancer	0.000892	0.00951	CbGeAlD
Imatinib—PDGFRB—hematopoietic system—thymus cancer	0.000879	0.00936	CbGeAlD
Imatinib—LCK—bone marrow—thymus cancer	0.000874	0.00932	CbGeAlD
Imatinib—LCK—thyroid gland—thymus cancer	0.000872	0.00929	CbGeAlD
Imatinib—Rhinitis—Octreotide—thymus cancer	0.000861	0.00598	CcSEcCtD
Imatinib—Hepatitis—Octreotide—thymus cancer	0.000858	0.00597	CcSEcCtD
Imatinib—NQO2—cardiac atrium—thymus cancer	0.000857	0.00913	CbGeAlD
Imatinib—Hypoaesthesia—Octreotide—thymus cancer	0.000854	0.00594	CcSEcCtD
Imatinib—CA3—lung—thymus cancer	0.000852	0.00908	CbGeAlD
Imatinib—Pharyngitis—Octreotide—thymus cancer	0.000852	0.00592	CcSEcCtD
Imatinib—Oedema peripheral—Octreotide—thymus cancer	0.000846	0.00588	CcSEcCtD
Imatinib—NQO2—pituitary gland—thymus cancer	0.000837	0.00892	CbGeAlD
Imatinib—ORM1—hematopoietic system—thymus cancer	0.000825	0.00878	CbGeAlD
Imatinib—CA1—hematopoietic system—thymus cancer	0.000823	0.00877	CbGeAlD
Imatinib—KIT—epithelium—thymus cancer	0.000823	0.00876	CbGeAlD
Imatinib—PDGFRB—epithelium—thymus cancer	0.000803	0.00856	CbGeAlD
Imatinib—Tinnitus—Octreotide—thymus cancer	0.0008	0.00556	CcSEcCtD
Imatinib—Flushing—Octreotide—thymus cancer	0.000797	0.00554	CcSEcCtD
Imatinib—Cardiac disorder—Octreotide—thymus cancer	0.000797	0.00554	CcSEcCtD
Imatinib—PDGFRA—lymphoid tissue—thymus cancer	0.000793	0.00844	CbGeAlD
Imatinib—LCK—lung—thymus cancer	0.000792	0.00844	CbGeAlD
Imatinib—ABL1—hematopoietic system—thymus cancer	0.000783	0.00835	CbGeAlD
Imatinib—Immune system disorder—Octreotide—thymus cancer	0.000775	0.00539	CcSEcCtD
Imatinib—Arrhythmia—Octreotide—thymus cancer	0.000767	0.00533	CcSEcCtD
Imatinib—Alopecia—Octreotide—thymus cancer	0.000758	0.00527	CcSEcCtD
Imatinib—CSF1R—cardiac atrium—thymus cancer	0.000753	0.00802	CbGeAlD
Imatinib—Mental disorder—Octreotide—thymus cancer	0.000752	0.00523	CcSEcCtD
Imatinib—Erythema—Octreotide—thymus cancer	0.000747	0.00519	CcSEcCtD
Imatinib—Malnutrition—Octreotide—thymus cancer	0.000747	0.00519	CcSEcCtD
Imatinib—Flatulence—Octreotide—thymus cancer	0.000736	0.00512	CcSEcCtD
Imatinib—CSF1R—pituitary gland—thymus cancer	0.000735	0.00783	CbGeAlD
Imatinib—NQO2—bone marrow—thymus cancer	0.000723	0.00771	CbGeAlD
Imatinib—Back pain—Octreotide—thymus cancer	0.000723	0.00502	CcSEcCtD
Imatinib—NQO2—thyroid gland—thymus cancer	0.000722	0.00769	CbGeAlD
Imatinib—PDGFRA—thyroid gland—thymus cancer	0.00072	0.00767	CbGeAlD
Imatinib—Muscle spasms—Octreotide—thymus cancer	0.000718	0.00499	CcSEcCtD
Imatinib—CA2—neck—thymus cancer	0.000717	0.00764	CbGeAlD
Imatinib—Vision blurred—Octreotide—thymus cancer	0.000704	0.0049	CcSEcCtD
Imatinib—Tremor—Octreotide—thymus cancer	0.0007	0.00487	CcSEcCtD
Imatinib—CSF1R—lymphoid tissue—thymus cancer	0.000698	0.00743	CbGeAlD
Imatinib—Ill-defined disorder—Octreotide—thymus cancer	0.000693	0.00482	CcSEcCtD
Imatinib—Anaemia—Octreotide—thymus cancer	0.000691	0.0048	CcSEcCtD
Imatinib—Malaise—Octreotide—thymus cancer	0.000674	0.00468	CcSEcCtD
Imatinib—SLC47A1—pituitary gland—thymus cancer	0.000671	0.00715	CbGeAlD
Imatinib—Vertigo—Octreotide—thymus cancer	0.000671	0.00467	CcSEcCtD
Imatinib—Syncope—Octreotide—thymus cancer	0.00067	0.00466	CcSEcCtD
Imatinib—KIT—pituitary gland—thymus cancer	0.000668	0.00711	CbGeAlD
Imatinib—PDGFRB—cardiac atrium—thymus cancer	0.000667	0.00711	CbGeAlD
Imatinib—Palpitations—Octreotide—thymus cancer	0.00066	0.00459	CcSEcCtD
Imatinib—Loss of consciousness—Octreotide—thymus cancer	0.000657	0.00457	CcSEcCtD
Imatinib—NQO2—lung—thymus cancer	0.000655	0.00698	CbGeAlD
Imatinib—PDGFRA—lung—thymus cancer	0.000654	0.00697	CbGeAlD
Imatinib—Cough—Octreotide—thymus cancer	0.000652	0.00453	CcSEcCtD
Imatinib—PDGFRB—pituitary gland—thymus cancer	0.000652	0.00695	CbGeAlD
Imatinib—Convulsion—Octreotide—thymus cancer	0.000647	0.0045	CcSEcCtD
Imatinib—ABL2—lymph node—thymus cancer	0.000645	0.00687	CbGeAlD
Imatinib—Hypertension—Octreotide—thymus cancer	0.000645	0.00449	CcSEcCtD
Imatinib—Chest pain—Octreotide—thymus cancer	0.000636	0.00442	CcSEcCtD
Imatinib—Arthralgia—Octreotide—thymus cancer	0.000636	0.00442	CcSEcCtD
Imatinib—Myalgia—Octreotide—thymus cancer	0.000636	0.00442	CcSEcCtD
Imatinib—CSF1R—bone marrow—thymus cancer	0.000635	0.00677	CbGeAlD
Imatinib—Anxiety—Octreotide—thymus cancer	0.000634	0.00441	CcSEcCtD
Imatinib—CSF1R—thyroid gland—thymus cancer	0.000634	0.00675	CbGeAlD
Imatinib—KIT—lymphoid tissue—thymus cancer	0.000634	0.00675	CbGeAlD
Imatinib—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.000632	0.00439	CcSEcCtD
Imatinib—Discomfort—Octreotide—thymus cancer	0.000629	0.00437	CcSEcCtD
Imatinib—Dry mouth—Octreotide—thymus cancer	0.000622	0.00433	CcSEcCtD
Imatinib—PDGFRB—lymphoid tissue—thymus cancer	0.000619	0.00659	CbGeAlD
Imatinib—PIP4K2C—lymph node—thymus cancer	0.00061	0.0065	CbGeAlD
Imatinib—Oedema—Octreotide—thymus cancer	0.00061	0.00424	CcSEcCtD
Imatinib—Anaphylactic shock—Octreotide—thymus cancer	0.00061	0.00424	CcSEcCtD
Imatinib—Infection—Octreotide—thymus cancer	0.000606	0.00421	CcSEcCtD
Imatinib—CA12—lung—thymus cancer	0.000603	0.00643	CbGeAlD
Imatinib—Shock—Octreotide—thymus cancer	0.0006	0.00417	CcSEcCtD
Imatinib—Nervous system disorder—Octreotide—thymus cancer	0.000598	0.00416	CcSEcCtD
Imatinib—Thrombocytopenia—Octreotide—thymus cancer	0.000597	0.00415	CcSEcCtD
Imatinib—Tachycardia—Octreotide—thymus cancer	0.000595	0.00414	CcSEcCtD
Imatinib—ABL1—cardiac atrium—thymus cancer	0.000595	0.00634	CbGeAlD
Imatinib—Skin disorder—Octreotide—thymus cancer	0.000592	0.00412	CcSEcCtD
Imatinib—Hyperhidrosis—Octreotide—thymus cancer	0.00059	0.0041	CcSEcCtD
Imatinib—CA3—lymph node—thymus cancer	0.000583	0.00621	CbGeAlD
Imatinib—CYP2C19—hematopoietic system—thymus cancer	0.000582	0.0062	CbGeAlD
Imatinib—Anorexia—Octreotide—thymus cancer	0.000581	0.00404	CcSEcCtD
Imatinib—ABL1—pituitary gland—thymus cancer	0.000581	0.00619	CbGeAlD
Imatinib—CA1—lymphoid tissue—thymus cancer	0.000579	0.00617	CbGeAlD
Imatinib—SLC47A1—thyroid gland—thymus cancer	0.000579	0.00617	CbGeAlD
Imatinib—KIT—bone marrow—thymus cancer	0.000577	0.00615	CbGeAlD
Imatinib—CSF1R—lung—thymus cancer	0.000576	0.00613	CbGeAlD
Imatinib—KIT—thyroid gland—thymus cancer	0.000575	0.00613	CbGeAlD
Imatinib—PDGFRB—bone marrow—thymus cancer	0.000563	0.006	CbGeAlD
Imatinib—PDGFRB—thyroid gland—thymus cancer	0.000562	0.00599	CbGeAlD
Imatinib—Musculoskeletal discomfort—Octreotide—thymus cancer	0.000556	0.00386	CcSEcCtD
Imatinib—ABL1—lymphoid tissue—thymus cancer	0.000552	0.00588	CbGeAlD
Imatinib—Insomnia—Octreotide—thymus cancer	0.000552	0.00383	CcSEcCtD
Imatinib—Paraesthesia—Octreotide—thymus cancer	0.000548	0.00381	CcSEcCtD
Imatinib—Dyspnoea—Octreotide—thymus cancer	0.000544	0.00378	CcSEcCtD
Imatinib—Somnolence—Octreotide—thymus cancer	0.000542	0.00377	CcSEcCtD
Imatinib—LCK—lymph node—thymus cancer	0.000542	0.00577	CbGeAlD
Imatinib—Dyspepsia—Octreotide—thymus cancer	0.000537	0.00373	CcSEcCtD
Imatinib—CA2—hematopoietic system—thymus cancer	0.000533	0.00568	CbGeAlD
Imatinib—Decreased appetite—Octreotide—thymus cancer	0.00053	0.00369	CcSEcCtD
Imatinib—ORM1—bone marrow—thymus cancer	0.000529	0.00563	CbGeAlD
Imatinib—CA1—bone marrow—thymus cancer	0.000528	0.00562	CbGeAlD
Imatinib—Gastrointestinal disorder—Octreotide—thymus cancer	0.000526	0.00366	CcSEcCtD
Imatinib—Fatigue—Octreotide—thymus cancer	0.000526	0.00366	CcSEcCtD
Imatinib—SLC47A1—lung—thymus cancer	0.000526	0.0056	CbGeAlD
Imatinib—KIT—lung—thymus cancer	0.000523	0.00557	CbGeAlD
Imatinib—Constipation—Octreotide—thymus cancer	0.000521	0.00363	CcSEcCtD
Imatinib—Pain—Octreotide—thymus cancer	0.000521	0.00363	CcSEcCtD
Imatinib—PDGFRB—lung—thymus cancer	0.000511	0.00544	CbGeAlD
Imatinib—Feeling abnormal—Octreotide—thymus cancer	0.000503	0.00349	CcSEcCtD
Imatinib—ABL1—bone marrow—thymus cancer	0.000502	0.00535	CbGeAlD
Imatinib—ABL1—thyroid gland—thymus cancer	0.000501	0.00534	CbGeAlD
Imatinib—Gastrointestinal pain—Octreotide—thymus cancer	0.000499	0.00347	CcSEcCtD
Imatinib—CA2—epithelium—thymus cancer	0.000488	0.0052	CbGeAlD
Imatinib—Urticaria—Octreotide—thymus cancer	0.000484	0.00337	CcSEcCtD
Imatinib—Body temperature increased—Octreotide—thymus cancer	0.000482	0.00335	CcSEcCtD
Imatinib—Abdominal pain—Octreotide—thymus cancer	0.000482	0.00335	CcSEcCtD
Imatinib—ORM1—lung—thymus cancer	0.000479	0.0051	CbGeAlD
Imatinib—CA1—lung—thymus cancer	0.000478	0.00509	CbGeAlD
Imatinib—CYP1A2—hematopoietic system—thymus cancer	0.000475	0.00507	CbGeAlD
Imatinib—CYP3A5—hematopoietic system—thymus cancer	0.000459	0.00489	CbGeAlD
Imatinib—ABL1—lung—thymus cancer	0.000455	0.00485	CbGeAlD
Imatinib—CYP2C9—hematopoietic system—thymus cancer	0.000451	0.00481	CbGeAlD
Imatinib—Hypersensitivity—Octreotide—thymus cancer	0.000449	0.00312	CcSEcCtD
Imatinib—NQO2—lymph node—thymus cancer	0.000448	0.00478	CbGeAlD
Imatinib—PDGFRA—lymph node—thymus cancer	0.000447	0.00476	CbGeAlD
Imatinib—Asthenia—Octreotide—thymus cancer	0.000438	0.00304	CcSEcCtD
Imatinib—Pruritus—Octreotide—thymus cancer	0.000431	0.003	CcSEcCtD
Imatinib—Diarrhoea—Octreotide—thymus cancer	0.000417	0.0029	CcSEcCtD
Imatinib—PTGS1—hematopoietic system—thymus cancer	0.000412	0.00439	CbGeAlD
Imatinib—CA2—cardiac atrium—thymus cancer	0.000405	0.00432	CbGeAlD
Imatinib—Dizziness—Octreotide—thymus cancer	0.000403	0.0028	CcSEcCtD
Imatinib—CA2—pituitary gland—thymus cancer	0.000396	0.00422	CbGeAlD
Imatinib—CSF1R—lymph node—thymus cancer	0.000394	0.00419	CbGeAlD
Imatinib—Vomiting—Octreotide—thymus cancer	0.000388	0.0027	CcSEcCtD
Imatinib—Rash—Octreotide—thymus cancer	0.000384	0.00267	CcSEcCtD
Imatinib—Dermatitis—Octreotide—thymus cancer	0.000384	0.00267	CcSEcCtD
Imatinib—Headache—Octreotide—thymus cancer	0.000382	0.00266	CcSEcCtD
Imatinib—PTGS1—epithelium—thymus cancer	0.000377	0.00401	CbGeAlD
Imatinib—CA2—lymphoid tissue—thymus cancer	0.000376	0.004	CbGeAlD
Imatinib—ABCG2—pituitary gland—thymus cancer	0.000366	0.0039	CbGeAlD
Imatinib—Nausea—Octreotide—thymus cancer	0.000362	0.00252	CcSEcCtD
Imatinib—SLC47A1—lymph node—thymus cancer	0.00036	0.00383	CbGeAlD
Imatinib—KIT—lymph node—thymus cancer	0.000357	0.00381	CbGeAlD
Imatinib—PDGFRB—lymph node—thymus cancer	0.000349	0.00372	CbGeAlD
Imatinib—CYP3A4—hematopoietic system—thymus cancer	0.000344	0.00367	CbGeAlD
Imatinib—CA2—bone marrow—thymus cancer	0.000342	0.00364	CbGeAlD
Imatinib—CA2—thyroid gland—thymus cancer	0.000341	0.00363	CbGeAlD
Imatinib—CYP2D6—hematopoietic system—thymus cancer	0.000339	0.00361	CbGeAlD
Imatinib—ORM1—lymph node—thymus cancer	0.000328	0.00349	CbGeAlD
Imatinib—CA1—lymph node—thymus cancer	0.000327	0.00348	CbGeAlD
Imatinib—ABCG2—bone marrow—thymus cancer	0.000317	0.00337	CbGeAlD
Imatinib—ABCG2—thyroid gland—thymus cancer	0.000316	0.00337	CbGeAlD
Imatinib—PTGS1—cardiac atrium—thymus cancer	0.000313	0.00333	CbGeAlD
Imatinib—ABL1—lymph node—thymus cancer	0.000311	0.00332	CbGeAlD
Imatinib—CA2—lung—thymus cancer	0.00031	0.0033	CbGeAlD
Imatinib—PTGS1—pituitary gland—thymus cancer	0.000306	0.00326	CbGeAlD
Imatinib—CYP1A2—thyroid gland—thymus cancer	0.000304	0.00324	CbGeAlD
Imatinib—ALB—lymph node—thymus cancer	0.000287	0.00306	CbGeAlD
Imatinib—ABCG2—lung—thymus cancer	0.000287	0.00306	CbGeAlD
Imatinib—CYP1A2—lung—thymus cancer	0.000276	0.00294	CbGeAlD
Imatinib—CYP3A5—lung—thymus cancer	0.000266	0.00284	CbGeAlD
Imatinib—PTGS1—thyroid gland—thymus cancer	0.000263	0.00281	CbGeAlD
Imatinib—ABCB1—hematopoietic system—thymus cancer	0.000244	0.0026	CbGeAlD
Imatinib—PTGS1—lung—thymus cancer	0.000239	0.00255	CbGeAlD
Imatinib—ABCB1—epithelium—thymus cancer	0.000223	0.00237	CbGeAlD
Imatinib—CA2—lymph node—thymus cancer	0.000212	0.00226	CbGeAlD
Imatinib—ABCG2—lymph node—thymus cancer	0.000196	0.00209	CbGeAlD
Imatinib—ABCB1—pituitary gland—thymus cancer	0.000181	0.00193	CbGeAlD
Imatinib—ABCB1—lymphoid tissue—thymus cancer	0.000172	0.00183	CbGeAlD
Imatinib—PTGS1—lymph node—thymus cancer	0.000164	0.00174	CbGeAlD
Imatinib—ABCB1—bone marrow—thymus cancer	0.000156	0.00166	CbGeAlD
Imatinib—ABCB1—thyroid gland—thymus cancer	0.000156	0.00166	CbGeAlD
Imatinib—ABCB1—lung—thymus cancer	0.000141	0.00151	CbGeAlD
Imatinib—ABCB1—lymph node—thymus cancer	9.68e-05	0.00103	CbGeAlD
Imatinib—PDGFRB—Signaling by NGF—KIT—thymus cancer	5.63e-05	0.00149	CbGpPWpGaD
Imatinib—NTRK1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	5.62e-05	0.00149	CbGpPWpGaD
Imatinib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	5.61e-05	0.00148	CbGpPWpGaD
Imatinib—PDGFRA—PI-3K cascade—AKT1—thymus cancer	5.61e-05	0.00148	CbGpPWpGaD
Imatinib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	5.61e-05	0.00148	CbGpPWpGaD
Imatinib—LCK—TCR signaling in naïve CD4+ T cells—AKT1—thymus cancer	5.57e-05	0.00147	CbGpPWpGaD
Imatinib—PDGFRA—PI3K/AKT activation—AKT1—thymus cancer	5.48e-05	0.00145	CbGpPWpGaD
Imatinib—PDGFRA—GAB1 signalosome—AKT1—thymus cancer	5.44e-05	0.00144	CbGpPWpGaD
Imatinib—LCK—Costimulation by the CD28 family—AKT1—thymus cancer	5.44e-05	0.00144	CbGpPWpGaD
Imatinib—NTRK1—Circadian rythm related genes—TP53—thymus cancer	5.39e-05	0.00143	CbGpPWpGaD
Imatinib—ABCG2—HIF-1-alpha transcription factor network—AKT1—thymus cancer	5.39e-05	0.00143	CbGpPWpGaD
Imatinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—thymus cancer	5.36e-05	0.00142	CbGpPWpGaD
Imatinib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	5.31e-05	0.0014	CbGpPWpGaD
Imatinib—NTRK1—MAPK Signaling Pathway—AKT1—thymus cancer	5.26e-05	0.00139	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CYLD—thymus cancer	5.1e-05	0.00135	CbGpPWpGaD
Imatinib—PDGFRB—PI-3K cascade—AKT1—thymus cancer	5.06e-05	0.00134	CbGpPWpGaD
Imatinib—ABL1—Immune System—CYLD—thymus cancer	4.97e-05	0.00131	CbGpPWpGaD
Imatinib—PDGFRB—PI3K/AKT activation—AKT1—thymus cancer	4.94e-05	0.00131	CbGpPWpGaD
Imatinib—PDGFRB—GAB1 signalosome—AKT1—thymus cancer	4.9e-05	0.0013	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD8A—thymus cancer	4.81e-05	0.00127	CbGpPWpGaD
Imatinib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	4.79e-05	0.00127	CbGpPWpGaD
Imatinib—NTRK1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	4.75e-05	0.00125	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—IL2—thymus cancer	4.66e-05	0.00123	CbGpPWpGaD
Imatinib—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thymus cancer	4.6e-05	0.00122	CbGpPWpGaD
Imatinib—LCK—CXCR4-mediated signaling events—AKT1—thymus cancer	4.59e-05	0.00121	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD8A—thymus cancer	4.55e-05	0.0012	CbGpPWpGaD
Imatinib—ABL1—DNA Damage Response (only ATM dependent)—AKT1—thymus cancer	4.53e-05	0.0012	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—KIT—thymus cancer	4.51e-05	0.00119	CbGpPWpGaD
Imatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	4.51e-05	0.00119	CbGpPWpGaD
Imatinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—thymus cancer	4.49e-05	0.00119	CbGpPWpGaD
Imatinib—NTRK1—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	4.47e-05	0.00118	CbGpPWpGaD
Imatinib—KIT—Signaling by SCF-KIT—AKT1—thymus cancer	4.43e-05	0.00117	CbGpPWpGaD
Imatinib—KIT—Disease—MAML2—thymus cancer	4.38e-05	0.00116	CbGpPWpGaD
Imatinib—LCK—HIV Infection—CD4—thymus cancer	4.32e-05	0.00114	CbGpPWpGaD
Imatinib—KIT—Downstream signaling of activated FGFR—AKT1—thymus cancer	4.24e-05	0.00112	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by SCF-KIT—AKT1—thymus cancer	4.2e-05	0.00111	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—MAML2—thymus cancer	4.19e-05	0.00111	CbGpPWpGaD
Imatinib—KIT—Signaling by ERBB4—AKT1—thymus cancer	4.17e-05	0.0011	CbGpPWpGaD
Imatinib—CA9—Cellular responses to stress—TP53—thymus cancer	4.17e-05	0.0011	CbGpPWpGaD
Imatinib—PDGFRA—Disease—MAML2—thymus cancer	4.15e-05	0.0011	CbGpPWpGaD
Imatinib—ABL1—Integrated Breast Cancer Pathway—TP53—thymus cancer	4.13e-05	0.00109	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD8A—thymus cancer	4.1e-05	0.00109	CbGpPWpGaD
Imatinib—LCK—B Cell Receptor Signaling Pathway—AKT1—thymus cancer	4.09e-05	0.00108	CbGpPWpGaD
Imatinib—LCK—Immune System—CYLD—thymus cancer	4.09e-05	0.00108	CbGpPWpGaD
Imatinib—LCK—PI-3K cascade—AKT1—thymus cancer	4.06e-05	0.00107	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signaling of activated FGFR—AKT1—thymus cancer	4.01e-05	0.00106	CbGpPWpGaD
Imatinib—KIT—Downstream signal transduction—AKT1—thymus cancer	3.99e-05	0.00105	CbGpPWpGaD
Imatinib—KIT—Signaling by FGFR—AKT1—thymus cancer	3.97e-05	0.00105	CbGpPWpGaD
Imatinib—LCK—PI3K/AKT activation—AKT1—thymus cancer	3.96e-05	0.00105	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by ERBB4—AKT1—thymus cancer	3.95e-05	0.00104	CbGpPWpGaD
Imatinib—KIT—Signaling by ERBB2—AKT1—thymus cancer	3.95e-05	0.00104	CbGpPWpGaD
Imatinib—ALB—Folate Metabolism—TP53—thymus cancer	3.94e-05	0.00104	CbGpPWpGaD
Imatinib—LCK—GAB1 signalosome—AKT1—thymus cancer	3.93e-05	0.00104	CbGpPWpGaD
Imatinib—KIT—DAP12 signaling—AKT1—thymus cancer	3.93e-05	0.00104	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—IL2—thymus cancer	3.9e-05	0.00103	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	3.9e-05	0.00103	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—TP53—thymus cancer	3.89e-05	0.00103	CbGpPWpGaD
Imatinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	3.87e-05	0.00102	CbGpPWpGaD
Imatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	3.84e-05	0.00102	CbGpPWpGaD
Imatinib—ABL2—Developmental Biology—AKT1—thymus cancer	3.83e-05	0.00101	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by SCF-KIT—AKT1—thymus cancer	3.78e-05	0.001	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signal transduction—AKT1—thymus cancer	3.77e-05	0.000998	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by FGFR—AKT1—thymus cancer	3.75e-05	0.000993	CbGpPWpGaD
Imatinib—PDGFRB—Disease—MAML2—thymus cancer	3.74e-05	0.000989	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by ERBB2—AKT1—thymus cancer	3.74e-05	0.000988	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 signaling—AKT1—thymus cancer	3.72e-05	0.000983	CbGpPWpGaD
Imatinib—KIT—Signaling by FGFR in disease—AKT1—thymus cancer	3.7e-05	0.000977	CbGpPWpGaD
Imatinib—KIT—DAP12 interactions—AKT1—thymus cancer	3.7e-05	0.000977	CbGpPWpGaD
Imatinib—KIT—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.7e-05	0.000977	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	3.66e-05	0.000969	CbGpPWpGaD
Imatinib—KIT—Signaling by EGFR—AKT1—thymus cancer	3.66e-05	0.000969	CbGpPWpGaD
Imatinib—KIT—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.63e-05	0.00096	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling of activated FGFR—AKT1—thymus cancer	3.62e-05	0.000957	CbGpPWpGaD
Imatinib—KIT—Signaling by PDGF—AKT1—thymus cancer	3.61e-05	0.000956	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—KIT—thymus cancer	3.56e-05	0.000942	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB4—AKT1—thymus cancer	3.56e-05	0.000941	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by FGFR in disease—AKT1—thymus cancer	3.5e-05	0.000925	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 interactions—AKT1—thymus cancer	3.5e-05	0.000925	CbGpPWpGaD
Imatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.5e-05	0.000925	CbGpPWpGaD
Imatinib—ABL1—Integrated Breast Cancer Pathway—AKT1—thymus cancer	3.49e-05	0.000922	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR—AKT1—thymus cancer	3.47e-05	0.000917	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.44e-05	0.000909	CbGpPWpGaD
Imatinib—NTRK1—Signaling by NGF—AKT1—thymus cancer	3.44e-05	0.000909	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	3.42e-05	0.000905	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by PDGF—AKT1—thymus cancer	3.42e-05	0.000905	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—KIT—thymus cancer	3.42e-05	0.000905	CbGpPWpGaD
Imatinib—KIT—B Cell Activation—AKT1—thymus cancer	3.42e-05	0.000904	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signal transduction—AKT1—thymus cancer	3.4e-05	0.000899	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR—AKT1—thymus cancer	3.38e-05	0.000895	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB2—AKT1—thymus cancer	3.37e-05	0.00089	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 signaling—AKT1—thymus cancer	3.35e-05	0.000886	CbGpPWpGaD
Imatinib—PDGFRA—Focal Adhesion—AKT1—thymus cancer	3.3e-05	0.000874	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	3.3e-05	0.000873	CbGpPWpGaD
Imatinib—ABL1—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	3.3e-05	0.000872	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD8A—thymus cancer	3.29e-05	0.000871	CbGpPWpGaD
Imatinib—PDGFRA—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	3.29e-05	0.00087	CbGpPWpGaD
Imatinib—PDGFRB—MAPK Signaling Pathway—AKT1—thymus cancer	3.29e-05	0.000869	CbGpPWpGaD
Imatinib—KIT—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.27e-05	0.000866	CbGpPWpGaD
Imatinib—PDGFRA—B Cell Activation—AKT1—thymus cancer	3.24e-05	0.000856	CbGpPWpGaD
Imatinib—LCK—Cytokine Signaling in Immune system—IL2—thymus cancer	3.23e-05	0.000855	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—KIT—thymus cancer	3.21e-05	0.000849	CbGpPWpGaD
Imatinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	3.15e-05	0.000833	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 interactions—AKT1—thymus cancer	3.15e-05	0.000833	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR in disease—AKT1—thymus cancer	3.15e-05	0.000833	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—KIT—thymus cancer	3.13e-05	0.000827	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR—AKT1—thymus cancer	3.12e-05	0.000826	CbGpPWpGaD
Imatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	3.1e-05	0.000819	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR in Cancer—AKT1—thymus cancer	3.1e-05	0.000819	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by PDGF—AKT1—thymus cancer	3.08e-05	0.000815	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—KIT—thymus cancer	3.08e-05	0.000815	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—MAML2—thymus cancer	3.07e-05	0.000812	CbGpPWpGaD
Imatinib—LCK—Signaling by SCF-KIT—AKT1—thymus cancer	3.03e-05	0.000802	CbGpPWpGaD
Imatinib—LCK—Disease—MAML2—thymus cancer	3e-05	0.000793	CbGpPWpGaD
Imatinib—PDGFRB—Focal Adhesion—AKT1—thymus cancer	2.98e-05	0.000787	CbGpPWpGaD
Imatinib—KIT—Immune System—CD8A—thymus cancer	2.92e-05	0.000772	CbGpPWpGaD
Imatinib—PDGFRB—B Cell Activation—AKT1—thymus cancer	2.92e-05	0.000771	CbGpPWpGaD
Imatinib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	2.92e-05	0.000771	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—MAML2—thymus cancer	2.91e-05	0.000768	CbGpPWpGaD
Imatinib—LCK—Downstream signaling of activated FGFR—AKT1—thymus cancer	2.9e-05	0.000768	CbGpPWpGaD
Imatinib—ABL1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	2.89e-05	0.000764	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—CD4—thymus cancer	2.88e-05	0.000761	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB4—AKT1—thymus cancer	2.86e-05	0.000755	CbGpPWpGaD
Imatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.79e-05	0.000738	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—CD4—thymus cancer	2.76e-05	0.000731	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD8A—thymus cancer	2.76e-05	0.000731	CbGpPWpGaD
Imatinib—LCK—Downstream signal transduction—AKT1—thymus cancer	2.73e-05	0.000721	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—CD4—thymus cancer	2.72e-05	0.00072	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR—AKT1—thymus cancer	2.71e-05	0.000718	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB2—AKT1—thymus cancer	2.7e-05	0.000714	CbGpPWpGaD
Imatinib—LCK—DAP12 signaling—AKT1—thymus cancer	2.69e-05	0.000711	CbGpPWpGaD
Imatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	2.65e-05	0.000701	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—MAML2—thymus cancer	2.62e-05	0.000692	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—CD4—thymus cancer	2.62e-05	0.000692	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—KIT—thymus cancer	2.57e-05	0.000681	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—AKT1—thymus cancer	2.53e-05	0.000669	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—AKT1—thymus cancer	2.53e-05	0.000669	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	2.53e-05	0.000669	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—AKT1—thymus cancer	2.52e-05	0.000666	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—AKT1—thymus cancer	2.51e-05	0.000663	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD8A—thymus cancer	2.49e-05	0.000658	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—AKT1—thymus cancer	2.48e-05	0.000657	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—AKT1—thymus cancer	2.47e-05	0.000654	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—KIT—thymus cancer	2.47e-05	0.000654	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—CD4—thymus cancer	2.45e-05	0.000649	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—IL2—thymus cancer	2.44e-05	0.000646	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD8A—thymus cancer	2.43e-05	0.000641	CbGpPWpGaD
Imatinib—CA3—Metabolism—AKT1—thymus cancer	2.42e-05	0.000641	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—CD4—thymus cancer	2.39e-05	0.000632	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—AKT1—thymus cancer	2.38e-05	0.00063	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—CD4—thymus cancer	2.36e-05	0.000623	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—AKT1—thymus cancer	2.34e-05	0.000619	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—IL2—thymus cancer	2.33e-05	0.000617	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	2.24e-05	0.000592	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—AKT1—thymus cancer	2.15e-05	0.000568	CbGpPWpGaD
Imatinib—LCK—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.12e-05	0.00056	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—MAML2—thymus cancer	2.1e-05	0.000556	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—KIT—thymus cancer	2.07e-05	0.000549	CbGpPWpGaD
Imatinib—LCK—Hemostasis—IL2—thymus cancer	2.01e-05	0.000532	CbGpPWpGaD
Imatinib—LCK—Immune System—CD8A—thymus cancer	2e-05	0.000528	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—CD4—thymus cancer	1.97e-05	0.000521	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—KIT—thymus cancer	1.93e-05	0.000511	CbGpPWpGaD
Imatinib—PDGFRA—Disease—KIT—thymus cancer	1.92e-05	0.000507	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—CD4—thymus cancer	1.89e-05	0.0005	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—KIT—thymus cancer	1.87e-05	0.000494	CbGpPWpGaD
Imatinib—ABL1—Immune System—KIT—thymus cancer	1.82e-05	0.000482	CbGpPWpGaD
Imatinib—PDGFRB—Disease—KIT—thymus cancer	1.73e-05	0.000456	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—AKT1—thymus cancer	1.72e-05	0.000456	CbGpPWpGaD
Imatinib—KIT—Immune System—CD4—thymus cancer	1.68e-05	0.000443	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—CD4—thymus cancer	1.59e-05	0.00042	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—TP53—thymus cancer	1.57e-05	0.000415	CbGpPWpGaD
Imatinib—CA14—Metabolism—AKT1—thymus cancer	1.56e-05	0.000413	CbGpPWpGaD
Imatinib—KIT—Disease—CD4—thymus cancer	1.55e-05	0.000409	CbGpPWpGaD
Imatinib—KIT—Immune System—IL2—thymus cancer	1.54e-05	0.000408	CbGpPWpGaD
Imatinib—CA6—Metabolism—AKT1—thymus cancer	1.52e-05	0.000403	CbGpPWpGaD
Imatinib—LCK—Immune System—KIT—thymus cancer	1.5e-05	0.000397	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	1.48e-05	0.00039	CbGpPWpGaD
Imatinib—PDGFRA—Disease—CD4—thymus cancer	1.46e-05	0.000387	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—IL2—thymus cancer	1.46e-05	0.000386	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—AKT1—thymus cancer	1.44e-05	0.00038	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—CD4—thymus cancer	1.43e-05	0.000378	CbGpPWpGaD
Imatinib—CA7—Metabolism—AKT1—thymus cancer	1.42e-05	0.000376	CbGpPWpGaD
Imatinib—ABL1—Immune System—CD4—thymus cancer	1.39e-05	0.000368	CbGpPWpGaD
Imatinib—LCK—Disease—KIT—thymus cancer	1.38e-05	0.000366	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—AKT1—thymus cancer	1.38e-05	0.000365	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—IL2—thymus cancer	1.36e-05	0.00036	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—AKT1—thymus cancer	1.36e-05	0.000359	CbGpPWpGaD
Imatinib—ABL1—Developmental Biology—AKT1—thymus cancer	1.35e-05	0.000357	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—KIT—thymus cancer	1.34e-05	0.000355	CbGpPWpGaD
Imatinib—ABL1—Hemostasis—AKT1—thymus cancer	1.33e-05	0.000351	CbGpPWpGaD
Imatinib—PDGFRB—Disease—CD4—thymus cancer	1.32e-05	0.000349	CbGpPWpGaD
Imatinib—CA12—Metabolism—AKT1—thymus cancer	1.32e-05	0.000348	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—IL2—thymus cancer	1.32e-05	0.000348	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—AKT1—thymus cancer	1.31e-05	0.000345	CbGpPWpGaD
Imatinib—LCK—Hemostasis—TP53—thymus cancer	1.29e-05	0.000342	CbGpPWpGaD
Imatinib—ABL1—Immune System—IL2—thymus cancer	1.28e-05	0.000339	CbGpPWpGaD
Imatinib—ALB—Platelet activation, signaling and aggregation—AKT1—thymus cancer	1.27e-05	0.000335	CbGpPWpGaD
Imatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	1.25e-05	0.00033	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—AKT1—thymus cancer	1.22e-05	0.000324	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—KIT—thymus cancer	1.21e-05	0.00032	CbGpPWpGaD
Imatinib—ALB—Hemostasis—IL2—thymus cancer	1.2e-05	0.000318	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—AKT1—thymus cancer	1.19e-05	0.000316	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—AKT1—thymus cancer	1.18e-05	0.000311	CbGpPWpGaD
Imatinib—LCK—Immune System—CD4—thymus cancer	1.15e-05	0.000303	CbGpPWpGaD
Imatinib—LCK—Hemostasis—AKT1—thymus cancer	1.09e-05	0.000289	CbGpPWpGaD
Imatinib—LCK—Disease—CD4—thymus cancer	1.06e-05	0.00028	CbGpPWpGaD
Imatinib—LCK—Immune System—IL2—thymus cancer	1.06e-05	0.000279	CbGpPWpGaD
Imatinib—CA2—Metabolism—AKT1—thymus cancer	1.01e-05	0.000266	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—IL2—thymus cancer	9.97e-06	0.000264	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—AKT1—thymus cancer	9.83e-06	0.00026	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—KIT—thymus cancer	9.7e-06	0.000256	CbGpPWpGaD
Imatinib—CA1—Metabolism—AKT1—thymus cancer	9.65e-06	0.000255	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—IL2—thymus cancer	9.44e-06	0.00025	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—AKT1—thymus cancer	9.44e-06	0.00025	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—TP53—thymus cancer	8.74e-06	0.000231	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—IL2—thymus cancer	8.5e-06	0.000225	CbGpPWpGaD
Imatinib—CA9—Metabolism—AKT1—thymus cancer	8.48e-06	0.000224	CbGpPWpGaD
Imatinib—KIT—Immune System—AKT1—thymus cancer	8.36e-06	0.000221	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—AKT1—thymus cancer	7.92e-06	0.000209	CbGpPWpGaD
Imatinib—ALB—Hemostasis—TP53—thymus cancer	7.73e-06	0.000204	CbGpPWpGaD
Imatinib—KIT—Disease—AKT1—thymus cancer	7.72e-06	0.000204	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—AKT1—thymus cancer	7.38e-06	0.000195	CbGpPWpGaD
Imatinib—PDGFRA—Disease—AKT1—thymus cancer	7.31e-06	0.000193	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—AKT1—thymus cancer	7.13e-06	0.000189	CbGpPWpGaD
Imatinib—ABL1—Immune System—AKT1—thymus cancer	6.95e-06	0.000184	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—IL2—thymus cancer	6.82e-06	0.00018	CbGpPWpGaD
Imatinib—PDGFRB—Disease—AKT1—thymus cancer	6.58e-06	0.000174	CbGpPWpGaD
Imatinib—ALB—Hemostasis—AKT1—thymus cancer	6.52e-06	0.000173	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—TP53—thymus cancer	6.4e-06	0.000169	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—TP53—thymus cancer	6.06e-06	0.00016	CbGpPWpGaD
Imatinib—LCK—Immune System—AKT1—thymus cancer	5.72e-06	0.000151	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—TP53—thymus cancer	5.46e-06	0.000144	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—AKT1—thymus cancer	5.41e-06	0.000143	CbGpPWpGaD
Imatinib—LCK—Disease—AKT1—thymus cancer	5.28e-06	0.00014	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—AKT1—thymus cancer	5.12e-06	0.000135	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—AKT1—thymus cancer	4.61e-06	0.000122	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—TP53—thymus cancer	4.38e-06	0.000116	CbGpPWpGaD
Imatinib—ABCG2—Metabolism—AKT1—thymus cancer	4.29e-06	0.000113	CbGpPWpGaD
Imatinib—CYP3A7—Metabolism—AKT1—thymus cancer	4.25e-06	0.000112	CbGpPWpGaD
Imatinib—SLC22A2—Metabolism—AKT1—thymus cancer	4.24e-06	0.000112	CbGpPWpGaD
Imatinib—PTGS1—Metabolism—AKT1—thymus cancer	4.12e-06	0.000109	CbGpPWpGaD
Imatinib—SLC22A1—Metabolism—AKT1—thymus cancer	3.95e-06	0.000105	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—AKT1—thymus cancer	3.7e-06	9.79e-05	CbGpPWpGaD
Imatinib—CYP3A5—Metabolism—AKT1—thymus cancer	3.07e-06	8.12e-05	CbGpPWpGaD
Imatinib—ALB—Metabolism—AKT1—thymus cancer	2.65e-06	7e-05	CbGpPWpGaD
Imatinib—CYP2C19—Metabolism—AKT1—thymus cancer	2.37e-06	6.28e-05	CbGpPWpGaD
Imatinib—ABCB1—Metabolism—AKT1—thymus cancer	2.32e-06	6.13e-05	CbGpPWpGaD
Imatinib—CYP2D6—Metabolism—AKT1—thymus cancer	2.18e-06	5.78e-05	CbGpPWpGaD
Imatinib—CYP2C9—Metabolism—AKT1—thymus cancer	2.17e-06	5.73e-05	CbGpPWpGaD
Imatinib—CYP1A2—Metabolism—AKT1—thymus cancer	1.85e-06	4.89e-05	CbGpPWpGaD
Imatinib—CYP3A4—Metabolism—AKT1—thymus cancer	1.43e-06	3.78e-05	CbGpPWpGaD
